Vinblastine

Vinblastine

Clinical data
Trade names	Velban, others
AHFS/Drugs.com	Monograph
MedlinePlus	a682848
Pregnancy category	AU: D US: D (Evidence of risk)
Routes of administration	intravenous
ATC code	L01CA01 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	n/a
Metabolism	Liver (CYP3A4-mediated)
Biological half-life	24.8 hours (terminal)
Excretion	Biliary and kidney
Identifiers
IUPAC name dimethyl (2β,3β,4β,5α,12β,19α)-15-[(5S,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indol- 9-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3,4-dicarboxylate
Synonyms	vincaleukoblastine
CAS Number	865-21-4 Y
PubChem CID	241903
DrugBank	DB00570 Y
ChemSpider	211446 Y
UNII	5V9KLZ54CY
KEGG	D08675 Y
ChEBI	CHEBI:27375 Y
ChEMBL	CHEMBL159 N
NIAID ChemDB	002673
ECHA InfoCard	100.011.577
Chemical and physical data
Formula	C46H58N4O9
Molar mass	810.975 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(OC)[C@]4(c2c(c1ccccc1n2)CCN3C[C@](O)(CC)C[C@@H](C3)C4)c5c(OC)cc6c(c5)[C@@]89[C@@H](N6C)[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[C@@]7(/C=C\CN([C@@H]78)CC9)CC
InChI InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1 Y Key:JXLYSJRDGCGARV-XQKSVPLYSA-N Y
NY (what is this?)

Vinblastine is a chemotherapy medication, typically used with other medications, to treat a number of types of cancer. This includes Hodgkin's lymphoma, non-small cell lung cancer, bladder cancer, brain cancer, melanoma, and testicular cancer. It is given by injection into a vein.

Most people experience some side effects. Commonly it causes a change in sensation, constipation, weakness, loss of appetite, and headaches. Severe side effects include low blood cell counts and shortness of breath. It should not be given to people who have a current bacterial infection. Use during pregnancy will likely harm the baby. Vinblastine works by blocking cell division.

Vinblastine was isolated in 1958. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. As of 2014 the wholesale cost in the developing world is about 7.70 and 31.70 USD per dose. In the United Kingdom it costs 13.09 pounds per 10 mg vial. It was originally obtained from the Madagascar periwinkle.

Vinblastine is a component of a number of chemotherapy regimens, including ABVD for Hodgkin lymphoma. It is also used to treat histiocytosis according to the established protocols of the Histiocytosis Association.